Roche Forays in Rare Diseases by Licensing PTC Therapeutics’ Spinal Muscular Atrophy Programme
By Heather Cartwright
Pharma Deals Review: Vol 2011 Issue 12 (Table of Contents)
Published: 22 Dec-2011
DOI: 10.3833/pdr.v2011.i12.1638 ISSN: 1756-7874
Section: Research & Development
Fulltext:
Abstract
Roche and PTC Therapeutics have partnered for the second time in a novel three-way collaboration that sees Roche obtain a worldwide licence to PTC’s spinal muscular atrophy (SMA) programme, which includes three preclinical-stage assets as well as potential back-up compounds...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS